drugset
drugset / Trial / NCT05347394

A Phase 1 Dose Escalation Study of Oral VX-708 in Healthy Participants

NCT05347394 ↗

Phase 1 Completed 100 enrolled Vertex Pharmaceuticals Incorporated
RandomizedSequentialQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple ascending doses of VX-708 in healthy participants.

Timeline

Start
2022-04-08
Primary completion
2023-04-14
Completion
2023-04-14

Drugs

EvaluationDrugModalityDoseRoute
Subject VX-708 Unknown — Oral

Indications

No indication recorded.